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Abstract  
Between January 1985 and December 1988, 20 patients over the age of 55 years (extremes 56-63 years; 15 men 
and 5 women) underwent cardiac transplantation. The cause of cardiopathy was ischemic in 70% of the cases. 
The immunosuppressive regimen consisted of cyclosporin A, corticoids, and azathioprine. Rejection episodes 
were monitored by endomyocardial biopsies and treated by pulses of corticoids or monoclonal antibodies (OKT 
3). The operative mortality was 10% (n = 2). The 1-year survival rate was 70%. The 1-year incidence of 
infection and/or rejection episodes was 1 and 1.53 episodes/ patient, respectively. One patient was successfully 
retransplanted after 9 months because of intractable rejection. Age beyond 55 years is no longer a 
contraindication to cardiac transplantation. This change in recipient selection policy should lead to parallel 
changes in donor selection criteria. 
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Since the first human heart transplant in 1967 [1], the 1-year survival rate has gradually risen from 20% to 65% 
[3,4,14]. Adherence to strict criteria in recipient selection was deemed essential in order to achieve good results. 
In particular, until very recently, an age limit of 50-55 years was the standard protocol [10]. The reported 1-year 
survival rate was less than 40% in patients older than 50 years, and age beyond 55 years was considered a major 
contraindication to cardiac transplantation [7]. 
In 1981 the introduction of cyclosporin A to the immunosuppressive regimen reduced the risk of infection and 
rejection. This important step led to an increase in actuarial 1-year survival to more than 80% [6]. 
As a consequence of improved results, recipient selection criteria have been altered so as to provide maximal 
benefit to the greatest number of patients. Now, clinicians confronted with "high-risk" cardiac patients may 
select transplantation as the best therapeutic choice. At the same time, progress in medical therapy now makes it 
possible for a greater number of older patients to sustain cardiac insufficiency and to become candidates for 
cardiac transplantation. Some centers have been encouraged to raise the age limit [5,8,11,12]. Recent studies 
have failed to demonstrate increased risk in patients over 50 years of age. This report details our experience with 
patients beyond 55 years of age. 
Patients and methods 
Between January 1985 and December 1988, twenty patients over the age of 55 years (extremes 56-63 years) 
underwent orthotopic cardiac transplantation. The general characteristics of the patients are summarized in Table 
1. Six of the 20 patients (30%) had had previous cardiac surgery: 5 aortocoronary bypasses (1-10 years before) 
and 1 aortic valvular replacement (15 years before). Past noncardiac medical history included insulin-dependent 
diabetes mellitus (n = 1), emphysema due to anthracosilicosis (n = 1), and renal dysfunction related to vascular 
atrophy of the right kidney (creatinine clearance 40 ml/min; n = 1). One patient with end-stage renal failure due 
to renal polykistosis received a kidney graft simultaneously with the cardiac transplant. 
All patients were screened for cytomegalovirus, hepatitis, human immunodeficiency virus, and toxoplasmosis. 
Donors were matched according to ABO blood group compatibility. Donor hearts were evaluated with 
electrocardiograms, cardiac echocardiograms, and creatine kinase isoenzymes. For donors beyond 40 years, a 
coronarography was obtained whenever possible. Serologic tests were routinely performed. After transplantation 
all patients received an immunosuppressive therapy based on corticoids, azathioprine and cyclosporin A, as 
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shown in Table 2. Dosages of cyclosporin were adjusted to maintain whole blood levels of 150-400 ng/ml for the 
first 3 months and were gradually decreased to 100-150 ng/ml. A monoclonal radioimmunoassay was used for 
dosages. Monitoring of rejection episodes was achieved by means of serial endomyocardial biopsies performed 
on a routine basis or more often if necessary. The Billingham criteria for determination of the presence and 
severity of rejection were used [2]. Only the stage 2 A and B or 3 rejection episodes were treated (interstitial 
aggregation of mononuclear cells and foci of myocyte degeneration of various importance; Table 3). In addition 
to the immunosuppressive treatment, prophylaxis of stress ulcus was instituted with ranitidine (800 mg/day for 6 
months). Invasive herpetic infection was prevented by acyclovir intake for 6 months. Vitamin D and calcium 
supplementation was directed against corticoid-indiced osteoporosis. 
 
Table 1. Characteristics of the patients 
Stage IV functional class (New York Heart Association) 
Age beyond 55 years (extremes 56-63 years) 
15 men, 5 women 
Origin of the cardiopathy: 
Ischemic: n = 14 (70%) 
Idiopathic: n = 5 (25%) 
Valvular:n = 1 (5%) 
Previous cardiac surgery: n = 6 (30%) 
 
Table 2. Immunosuppressive protocol 
Corticoids 
Methylprednisolone 
500 mg IV intraoperatively 
8 mg/kg per day on day 1 to 1 mg/kg per day on day 5 
Oral prednisone 
1 mg/kg per day on day 6 to 16 mg/day at 6 weeks 
(progressive reduction of doses) 
Cyclosporin A 
Beginning after 24 or 48 h, according to renal function 
Serum levels 
150-400 ng/ml for the first 3 months 
100-150 ng/ml after 3 months 
Azathioprine 
3 mg/kg IV on days 1 and 2 
2-3 mg/kg per day orally, according to hematologic and hepatic 
tolerances 
 
Table 3. Treatment of rejection episodes 
Stage 2A 
Bolus of methylprednisolone 
(1.5 mg/kg per day for 3-4 days) 
Stage 2B-3 
OKT3 (5 mg/day IV for 14 days) 
CyA suppressed during OKT3 therapy, same dosages of 
azathioprine and corticoids 
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Table 4. Results 
Operative mortality: n = 2 (10%) 
2 right cardiac failure  
1-year survival: n = 14 (70%) 
4 deaths due to infection: 1 cerebral abscess 
 1 disseminated toxoplasmosis 
 2 confluent bronchopneumonia 
Incidence of infection: 1     ± 1.03 episodes/patient 
Incidence of rejection: 1.53 ± 0.94 episodes/patient 
 
Results (Table 4) 
The operative mortality was 10% (n = 2). Two patients died from right cardiac failure related to precapillar 
pulmonary hypertension. The mean follow-up period was 18 ± 3 months. The 1-year survival rate was 70%. All 
patients who survived beyond the first year post-transplantation are still alive. The longest survival to date is 4 
years. 
Five nonfatal bacterial infections were observed. One mediastinitis and one pyopneumothorax were successfully 
treated by closed drainage and continuous irrigation with iodine povidone and intravenous antibiotherapy. Two 
bronchopneumoniae and one catheter-related septicemia responded well to intravenous antibiotherapy. Eight 
reactivations of past viral infections were noted: cytomegalovirus (n = 2), herpes (n = 3), zona (n = 2) and 
Epstein-Barr (n = 1). Thus, the 1st year incidence of fatal and nonfatal infections was 1 ± 1.03 episodes/patient. 
The 1st year incidence of rejection was 1.53 ± 0.94 episodes/patient. Three subjects received monoclonal 
antibodies (OKT3). One patient was successfully retransplanted after 9 months because of irreversible cardiac 
failure. Eleven patients were in functional class I and two in class II of the New York Heart Association. The 
retransplanted patient was, at the time of retransplantation, in class III and is presently in class I. 
A number of side effects of the immunosuppressive therapy were related to the cyclosporin, others to either 
azathioprine or the corticotherapy. Systemic hypertension (systolic blood pressure higher than 160 mmHg or 
diastolic blood pressure higher than 95 mmHg) developed in 11 subjects (78%). Hypertension was well 
controlled by nifedipine. Seven patients (50%) developed hypercholesterolemia (total cholesterol > 2.5 g/l). In 
three patients, the parameters of renal function changed with blood levels of urea of more than 1 g/1 and of 
serum creatinine of more than 20 mg/l. None of these patients required hemodialysis. Diabetic mellitus, brought 
under control by insulin therapy, appeared in three patients receiving pulses of corticoids to treat rejection 
episodes. Moderate anemia (one microcytic and five macrocytic) occurred six times and, in two cases, required 
discontinuation of azathioprine. Miscellaneous side effects of cyclosporine therapy were also observed. A gastric 
lymphoma occurred 3 years after transplantation, and the patient is presently cured, 1 year after partial 
gastrectomy. Two patients developed hypertrichosis, and handquicers were noted in three cases. 
Discussion 
In the early years of clinical heart transplantation, it was said that in addition to rigorous surgical and anesthetic 
techniques, adequate selection of the patient was the key to success [3,7,10]. Later, improvements in both 
recipient and donor management and standardization of immunosuppressive protocols led to the modification of 
some indications. The age of the patient was one of these contraindications. Age beyond 50-55 years was a limit 
since, in older patients, the incidence of infection increased and the ability to sustain surgery decreased, as did 
survival [7]. 
After the introduction of cyclosporin, which allows for a reduction in corticoid requirements [6], the risk of 
infection was greatly reduced, with a concomitant decrease in the rejection rate. Thus, the 1-year survival rate 
rose to more than 75%. This led to changes in the recipient selection criteria so as to provide maximal benefit to 
the greatest number of patients. Subsequently, some authors reported good results in patients older than 55 or 60 
years, results equal to those observed in many younger patients [5, 8, 11, 12]. Frazier et al. [8] reported a 1-year 
survival rate of 83% for patients over 60 years of age compared to one of 75% for other transplant patients. In 
the earlier study of Carrier et al. [5], actuarial survival at 1 year was 72% in patients over 50 years of age and 
66% in the group under 50 years of age. In the older age group, ischemic disease was the main cause of 
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cardiopathy: 64% [8]-69% [5] and 70% in our series. Previous cardiac surgery was frequent (30% in our series), 
something which tends to increase technical difficulties. The rates of infection or rejection episodes in elderly 
patients were not higher than those in the younger group [5, 8, 11,12]. Thus, these authors [5, 8] concluded that a 
rigidly determined age criterion for cardiac transplant was illogical. 
A large number of patients over 50 years of age may be considered suitable candidates for cardiac 
transplantation if disease of other systems is not present to limit survival [5]. But even this notion may be too 
rigid. In the report by Frazier et al. [8], the elderly group was at high surgical risk: all patients had preoperative 
renal dysfunction that complicated cyclosporin therapy and 35.7% were diabetic. That represents a major 
challenge in terms of steroid therapy and the prevention of infection. 
A combination of factors may explain the good results observed in patients over 55 years of age. First, 
cyclosporin improves immunosuppression and reduces the incidence of infection [6], Thus, older patients' 
susceptibility to infection has become a less important factor. Second, older patients may be more tolerant of the 
graft because of the ill-defined "immunosenescence" [8]. Previous blood transfusions, particularly at the time of 
previous coronary surgery, may have contributed to a decreased incidence of rejection [11,12]. 
Some side effects of the immunosuppressive agents were observed in our series. After transplantation 
hypertension occurred in 78% of the patients. This phenomenon is common and has reached 80%-100% in some 
series [9, 15]. High dosages of cyclosporin were considered the etiologic factor. However, in a recent study [13], 
hypertension developed in almost all patients after heart transplantation, despite the lower dosage of cyclosporin 
with a triple drug regimen and the absence of significant renal impairment. As we observed, this hypertension 
generally responds to the administration of diuretic agents and vasodilatator drugs (usually calcium channel 
blockers) [9,13,15]. Fifty percent of our patients also developed hypercholesterolemia, which may have 
deleterious effects on the graft function in conjunction with hypertension. Treatment of acute rejection with 
pulses of corticoids led three patients to develop diabetes mellitus, which was brought under control by insulin 
therapy. In contrast, no severe impairment of renal function was observed. 
We may conclude that the results of cardiac transplantation in patients of advanced age are equal to those 
obtained in a younger population, at least for the 1st year. 
Thus, a rigidly defined age criterion for potential cardiac recipients is not justified. It is illogical to refuse cardiac 
transplantation to patients who have often been treated medically for long periods of time and who need 
transplantation in order to survive. Adoption of such a policy would, in turn, necessitate a broadening of donor 
selection criteria, for without a parallel increase in potential donors, the number of deaths among potential 
candidates would certainly increase. In fact, few donors over the age of 45 years are used. Older donors, who are 
generally considered undesirable for young recipients, should be used for transplantation in the older recipient 
group. Provided the heart function is good (as assessed by echocardiography and, if necessary, by 
coronarography) and provided the donor is free of previous cardiac disease, this option could enlarge the donor 
pool. Moreover, older donor hearts are generally more capable of sustaining the high pulmonary resistance that is 
more frequently encountered in recipients of advanced age. 
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